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Abstract
Primary mediastinal B-cell lymphoma (PMBL) is a separate entity of aggressive B-cell lymphoma, characterized by a constitutive
activation of janus kinase - signal transducer and activator of transcription (JAK - STAT) signaling pathway, also observed in
Hodgkin lymphoma. Although many cancers exhibit constitutive JAK - STAT pathway activation, mutations of genes have notSTAT 
been reported in neoplasms. Here, we show that MedB-1 PMBL-derived and L1236 Hodgkin-derived cell lines and 20 of 55 (36 )%
PMBL cases harbor heterozygous missense mutations in STAT6 DNA binding domain, whereas no mutation was found in 25 diffuse
large B-cell lymphoma samples. In 3 cases, somatic origin was indicated by the absence of the mutations in the non tumoral tissue.
The pattern of mutations was different from the classical features of somatic hypermutations. The mutant STAT6 proteinsSTAT6 
showed a decreased DNA binding ability in transfected HEK cells, but no decrease in expression of STAT6 canonical target genes was
observed in PMBL cases with a mutated gene. Although the oncogenic properties of STAT6 mutant proteins remain to beSTAT6 
determined, their recurrent selection in PMBL strongly argues for their involvement in the pathogenesis of this aggressive B-cell
lymphoma.
MESH Keywords Cell Line, Tumor ; Female ; Gene Expression Regulation, Neoplastic ; genetics ; Humans ; Lymphoma, Large B-Cell, Diffuse ; genetics ; metabolism ; 
Male ; Mediastinal Neoplasms ; genetics ; metabolism ; Mutation ; genetics ; Neoplasm Proteins ; genetics ; metabolism ; Protein Structure, Tertiary ; genetics ; STAT6
Transcription Factor ; genetics ; metabolism ; Signal Transduction ; genetics
INTRODUCTION
Primary mediastinal B-cell lymphoma (PMBL) is recognized as a separate entity of aggressive B-cell lymphoma, with unique clinical,
histological, and biologic features. This lymphoma presents as a mediastinal mass consisting of large B cells, that usually express little if1 
any surface or cytoplasmic immunoglobulin and major histocompatibility complex class I and/or class II molecules and presumably derive
from a subset of thymic B cells. PMBL displays a constitutive activation of the JAK/STAT signaling pathway as indicated by the2 
presence of nuclear phosphorylated (P) STAT6, which is also observed in Hodgkin lymphoma. , STAT6 expression was shown to3 4 5 
regulate cell proliferation and survival in a PMBL derived cell line, MedB-1. These lymphomas harbor chromosomal gains of the 6 JAK2 
gene, and inactivating mutations of the Suppressor of Cytokine Signaling ( gene, which are also commonly found in Hodgkin7 SOCS)1 8 
lymphoma. , Although SOCS1 inactivation prevents STAT6 downregulation and thereby contributes to STAT6 activity, the primary9 10 6 
mechanism responsible for STAT6 activation remains unclear. PMBL do not secrete the specific cytokines (i.e., Interleukin -4 or -13)
classically involved in the activation of this factor, unlike classical Hodgkin lymphoma , and JAK2 inhibition only partially prevented11 12 
STAT6 activation in MedB-1.3
The analysis of STAT6 functional properties by directed mutagenesis has shown that a mutation in the SH2 domain (STAT6
V547A/T548A) leads to the constitutive activation of STAT6. This mutation changes the conformation of the protein and increases the13 
stability of the monomeric and dimeric proteins, allowing STAT6VT mutant protein to undergo tyrosine phosphorylation, followed by
DNA binding, in the absence of IL-4 stimulation. Transgenic mice expressing STAT6VT under control of the CD2 locus control region,
which essentially directs expression to the T-cell compartment, show increased peripheral B cell and decreased T cell numbers, and14 
develop, in a small proportion of cases, a spontaneous lymphoproliferative disease of T-cell or B-cell mixed phenotype. These data15 
prompted us to analyze the sequence of mRNA in MedB-1 and Karpas1106 PMBL derived cell lines and in a series of 55 primarySTAT6 
tumor samples. We found heterozygous mutations targeting the DNA binding domain in one cell line and 36  of the samples, and%
therefore, analyzed the histological, clinical and molecular characteristics of the PMBL cases with a mutation, as well as theSTAT6 
functional properties of the mutant STAT6 proteins.
STAT6 mutations in mediastinal B-cell lymphoma
Blood . Author manuscript
Page /2 10
MATERIAL AND METHODS
Tissue samples selection and DNA or RNA extraction
This study was approved by the Ethic Committee of the University of Ulm, Germany and the institutional review board comit  de“ é
protection des personnes Ile de France IX , Cr teil, France. A series of 55 primary mediastinal B-cell lymphoma (PMBL) and 25 diffuse” é
large B-cell lymphoma cases (DLBCL) were retrieved from the files of the Institute of Pathology, Ulm, Germany and of the Department of
Pathology, Hospital Henri Mondor, Cr teil, France. These lymphomas samples, initially diagnosed between 1984 and 2007, showed theé
histological features characteristic of these lymphoma types according to the recently updated WHO classification. The PMBL samples1 
had been previously immuno-phenotyped extensively and were included in several publications that contributed to define PMBL
characteristic features. , , Tumor infiltration of the frozen samples was checked on Hematoxylin Eosin Safran staining of tissue3 8 16 –19 
sections. Total RNA were extracted from frozen tissue samples with TRIZOL reagent (Invitrogen, Cergy Pontoise, France) or Qiagen
RNeasy mini kit (Qiagen, Hilden, Germany), according to the manufacturer s instructions. Genomic DNA was extracted with proteinase K’
digestion, phenol chloroform phases separation and ethanol precipitation.
Sequencing and quantitative Polymerase Chain Reaction (PCR)
Total RNA were reverse transcribed with Superscript II (Invitrogen, San Diego, CA) and poly-dT (500 ng) or random (300 ng) primers
in a final volume of 20 l, according to the manufacturer s instructions, and diluted 1:5 or 1:10 for PCR. Genomic DNA and cDNA wereμ ’
amplified by PCR using primers and detailed protocol indicated in . Purified PCR products were sequenced usingsupplementary methods 
BigDye Terminator v3.1 Cycle sequencing Kits (Applied Biosystems, Courtaboeuf, France) and capillary electrophoresis (3130 Genetic
analyser, Applied Biosystems). Sequences were analyzed with Seqscape software (Applied Biosystems) and standard electropherogram
reading programs (Chromas Lite, ). Nucleotide changes detected on one strand were confirmed by sequencing thewww.technelysium.com 
reverse strand. sequencing was performed on genomic DNA and cDNA in 25 cases (14 with and 11 without detected mutations),STAT6 
on cDNA only in 21 cases (4 with and 17 without detected mutations) or genomic DNA only in 9 cases (2 with and 7 without detected
mutations), depending on the material available. The alterations (mutations or microdeletions) were assessed on genomic DNASOCS1 
and cDNA (5 cases), on cDNA only (5 cases), or genomic DNA only (43 cases).
Genomic tumoral DNAs from the PMBL cases were also used for the quantitative analysis of the gene. Briefly, 50 ng DNAJAK2 
were amplified using the BioRad (Hercules, CA) Sybrgreen master mix and primers for and for (JAK2 B2M Table 1 in supplementary
) in a total reaction volume of 20 L in a BioRad I-cycler. Each PCR reaction was run in quadruplicate and the mean Ct valuesmethods μ
were used for further calculations. Relative gene dosage was calculated according to the 2 method. Genomic DNA isolatedJAK2 CT −ΔΔ 20 
from lymphocytes of 4 different healthy donors and from 7 frozen reactive tonsils were used to calculate the mean normal geneJAK2 
dosage. Tumor samples were considered to have a gain or amplification if the relative gene dosage was superior to meanJAK2 JAK2 
normal  3 Standard Derivation.+
Transfection, generation of the HEK stable transfectants and reporter assays
Wild type (WT) and double mutant (DM) STAT6 expression vectors were obtained by PCR amplification of coding sequenceSTAT6 
using cDNA from Ramos and MedB-1 cell line, respectively, and primers containing EcoR1 and XhoI restriction sides (underlined):
STAT6 for:5 -CGACGTG TGATGTCTCTGTGGGGTCTG-3 ; STAT6 rev: 5 -CAGTG′ GAATTC ′ ′ CTCGAG 
CTCACCAACTGGGGTTGGCCCT-3 ). PCR products were inserted into the Multiple Cloning Site of pcDNA3.1 expression vector′
(Invitrogen, Cergy Pontoise, France) and verified by sequencing. Single mutants were obtained by directed mutagenesis of WT STAT6
expression plasmids with the GeneEditor in Vitro Site-Directed Mutagenesis System (Promega, Madison, USA). WT STAT6 and DM
STAT6 expression plasmids or pcDNA-mock vector were transfected into HEK293 cell lines using Effectene Transfection Reagent
(Qiagen, Hilden, Germany) according to the manufacturer s instructions. 24h post transfection, 800 g/ml G418 (Invitrogen, Karlsruhe,’ μ
Germany) was added to the medium and HEK293 cells were cultured in the selection medium for 2 weeks before isolation of single clones
or pooling transfected cells. During analysis, the transfected cells were maintained under 600 g/ml of G418.μ
Firefly luciferase reporter vector containing (N3-luc) or not (control-luc) 3 copies of the N3 Gamma Activated Site (GAS) from CSN2 
(casein beta) promoter (TTCtagGAA) were obtained from Panomic (Panomic, Redwood City, CA). The N4-luc vector, comprising 3
STAT6 binding site from the promoter (TTCcgagGAA) upstream of the luciferase reporter gene was previously described.SOCS1 6 
HEK293 cells were transiently co-transfected using Effectene Transfection Reagent with control-luc, N3-luc or N4-luc reporter constructs
(1 g) in combination with either mock or WT STAT6 or one of the mutated STAT6 expression vectors (1 g). Forty ng of a μ μ Renilla 
luciferase reporter were added to each sample to normalize transfection efficiency. Luminescence intensity was measured using the
luminometer Lumat FB12 (Berthold Technologies, Bad Wildbach, Germany) and luciferase dual assay kit (Promega, Madison, USA)
according to the manufacturer s protocol.’
Western blotting and immunohistochemistry
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Western blots were performed as previously described. Proteins were detected using antibodies against STAT6 (M-200; sc-1698)6 
(Santa Cruz) 1:1000; P-STAT6 (Tyr641; 9361) (Cell Signaling, Beverly, MA) 1:1000; beta actin (clone AC-74), (Sigma-Aldrich, Saint
Louis, MO) 1:5000; HDAC1 (H-51) (Santa Cruz) 1:1000.
Immunohistochemistry was performed on paraffin section of formalin fixed tissue or on frozen sections. Paraffin sections were
pretreated for 20 min by steamer boiling in tris EDTA buffer (pH6). For detection of bound P-STAT6 antibody, the EnVision detection
system (Dako, Hamburg, Germany) was used with diamonobenzidine as substrate. The detection of P-STAT6 protein was checked in21 
control cells, i.e., interstitial fibroblastoid cells and a subset of endothelial cells, present in each tissue sample. Samples without positive
control cells were disregarded. P-STAT6 staining of neoplastic cells was considered positive whenever more than 5  of neoplastic cells%
had nuclear staining.
EMSA
N4 GAS probe from SOCS1 promoter (5  AGGTCGAC CAGAG 3  annealed with 5  AGGCTCTG′ TTCCCAAGAA ′ ′ TTCTTGGGAA 
GTCGA 3 ) and N3 GAS probe from the (casein beta) promoter (5  AGGAGAT TTCAATCC 3  annealed with 5′ CSN2 ′ TTCTAGGAA ′ ′
AGGGGATTGAA ATCT 3 ) were prepared. One g nuclear protein extracts from HEK293 stable pools (mock, WTTTCCTAGAA ′ μ
STAT6 and DM STAT6) were incubated with P-labelled N4 or N3 GAS probes, with or without 1 L anti-STAT6 antibody (S-20;32 μ
sc-621) (Santa Cruz) or a 100 fold molar excess cold probe and were separated on a 4  native acrylamide gel.%
RESULTS
Recurrent mutations of STAT6 DNA binding domain in MedB-1 cell line and PMBL primary tumors
We analyzed the entire coding sequence of mRNA in MedB-1 and Karpas1106 PMBL derived cell lines. Direct sequencing ofSTAT6 
PCR products showed that Karpas1106 cells carried wild type (WT) mRNA sequences, whereas MedB-1 cells exhibited twoSTAT6 
heterozygous missense mutations located in exon 12 (N417Y and N430T), which encodes part of the DNA binding domain. We amplified
MedB-1 exon 12 genomic DNA and sequenced cloned PCR products. Seven clones showed both N417Y and N430T mutations and two
were WT, indicating that both mutations were located on the same allele. These mutations were detected in the parental tumor from which
this cell line was established, but were absent in fibroblasts isolated from the same patient.22 
To evaluate the relevance of these mutations in PMBL, we sequenced the region of the gene encoding amino-acids L406 toSTAT6 
R527 in 55 PMBL and 25 aggressive B-cell lymphomas of the diffuse large B cell type. The DNA binding domain of STAT6 was found to
be mutated in 20 out of 55 (36 ) PMBL cases whereas no mutation was detected in the 25 diffuse large B cell lymphomas (Fisher s exact% ’
test, <0,0002). Interestingly, six PMBL cases had several missense mutations and one case had both a missense and a silent mutation (p 
). The 28 mutations that we detected were heterozygous and targeted preferentially A:T base pairs (20/28, exact binomial test, Figure 1a p 
0,0035) and AA, AG, AT or GA dinucleotides ( ). These mutations mostly affected exon 12, with four hotspots targeting amino= Table 1 
acid 417, 419, 421 and 430, respectively ( ). Of note, D419 is the site of a known polymorphism (D419N), which was notFigure 1b 
observed in the 80 lymphoma samples analyzed. Sequencing of genomic DNA derived from non-tumoral tissue of two mutated PMBL
cases revealed WT sequence, supporting a somatic origin of the mutations, as observed in MedB1/PMBL parental tumor. As Hodgkin
lymphoma cell lines also exhibit STAT6 activation and share some features with PMBL in gene expression profiles, , we sequenced5 19 23 
the same region of mRNA in 4 classical Hodgkin-derived cell lines. Strikingly, L1236 cell line, previously reported to have STAT6 
gene amplification and overexpression showed only expression of a mutated allele, encoding N417Y hotspot mutationSTAT6 24 STAT6 
and D419N polymorphic change ( ), while no mutation was detected in L428, L540 and KMH2 mRNA sequences.supplementary Figure 
Characteristics of the PMBL cases with a mutation of geneSTAT6 
The 20 PMBL cases with a mutated gene exhibited similar histological features (clear cells and fibrosis), and clinicalSTAT6 
characteristics as the 35 non-mutated ones ( ). Twelve PMBL cases previously shown to have a PMBL molecular signature, hadTable 2 19 
mutations in gene (7 cases) or not (5 cases). Intriguingly, the seven cases with multiple nucleotide changes presented aSTAT6 STAT6 
male predominance (M/F ratio  5/2) and a younger age at diagnosis (median 32 years) compared to the 13 cases with single nucleotide=
changes (M/F ratio  2/11, 0.02, Fisher s exact test; median age at diagnosis 41 years, 0.07, Wilcoxon rank sum test), suggesting that= p = ’ p =
a highly mutated phenotype might delineate a particular subset of PMBL patients.
P-STAT6 nuclear staining was detected in the nuclei of tumor cells in 31 of 35 (88 ) cases that could be evaluated ( ). It was% Table 2 
present in all mutated cases, but also in a large fraction of non-mutated cases, indicating that activation of STAT6 can occur in theSTAT6 
absence of mutation of the gene. gene deletions and/or mutations were observed in 34 of 52 (65 ) PMBL cases. gain orSOCS1 % JAK2 
amplification was observed in 22 of 47 (47 ) PMBL cases, at a similar frequency as that recently reported in a high resolution CGH array%
study. gene alterations and amplifications were present both in mutated cases and non-mutated cases ( ).25 SOCS1 JAK2 STAT6 Table 2 
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Out of the 47 cases that could be analyzed for all three genes, five showed no genetic alteration, 20 showed one alteration, 17 showed two
alterations and five cases had alterations of the 3 genes. Thus, it appears that the different genetic alterations of the JAK - STAT signaling
pathway are not mutually exclusive in PMBL, suggesting additive effects.
Functional properties of STAT6 mutant proteins
In order to evaluate the functional properties of the mutated STAT6 proteins, we transfected the HEK293 STAT6 deficient cell line
with expression vectors encoding either WT or N417/N430 double mutant (DM) STAT6, expressed in MedB-1/parental tumor and case
52. Independent stable pools and clones exhibited the same levels of basal and interleukin-4 (IL-4) induced STAT6 phosphorylation (
). DM STAT6 transfectants showed a decreased DNA binding activity on both N4 and N3 GAS sites (TTC N xGAA), comparedFigure 2a [ ]
to WT STAT6 expressing cells, although similar amounts of STAT6 and P-STAT6 were detected in the nucleus of WT and DM STAT6
expressing cells ( ). We hypothesized that the diminished DNA binding activity of STAT6 mutants might affect their ability toFigure 2b 
activate the expression of N4- or N3- GAS driven reporters. As shown in , HEK293 cells transiently transfected with doubleFigure 2c 
mutant or with N417Y, D419H, N421K, N430T STAT6 single mutants displayed reduced N4- and N3- sites driven reporter expression,
compared to WT STAT6 expressing cells, although achieving similar levels of P-STAT6 after IL-4 stimulation.
The decreased ability of STAT6 mutants to activate transcription was surprising considering the strong STAT6 signature previously
reported in gene expression profiling studies of PMBL. , We therefore compared the levels of expression of several genes which19 23 
contain confirmed STAT6 binding motifs in the 5 non-mutated and the 7 mutated cases which had been analyzed with microarrays as26 
part of a larger study. The levels of expression of these genes were similar in the two groups ( ), indicating that these mutations19 Table 3 
did not significantly impair the expression of these endogenous STAT6 targets in lymphoma cells.
DISCUSSION
PMBL is characterized by a constitutive activation of the JAK/STAT pathway, associated with gene defects and/or geneSOCS1 JAK2 
amplification, leading to STAT6 phosphorylation and DNA binding activity. In this study, we identified mutations affecting the STAT6
DNA binding domains in 20 of 55 (36 ) PMBL cases, but none of the 25 DLBCL tested. Although the constitutive activation of STAT%
proteins is a common finding in hematopoietic and non-hematopoietic cancers, this is the first observation of recurrent gene27 STAT 
mutations associated with human cancer. The seven PMBL cases with several nucleotide changes in sequence were mostly youngSTAT6 
males, and 3 of them had a rapidly fatal disease, highlighting the need of larger studies to address the association of mutation withSTAT6 
clinical presentation and outcome. It is noteworthy that the L1236 classical Hodgkin lymphoma cell line, which harbors an amplification
of the gene and which depends on IL-13 signaling for cell proliferation and viability, had an identical hotspot mutation inSTAT6 24 28 
STAT6 DNA binding domain. This finding extends the list of genetic alterations common to PMBL and classical Hodgkin lymphoma,
such as and genes gain/amplification, and gene deletions/mutations and supports the concept of a continuumREL JAK2 9 SOCS1 10 
between these two diseases, as acknowledged by the recognition of intermediate grey zone  lymphomas in the 2008 updated WHO“ ”
classification.1
Mutations of oncogenes have been shown to occur through aberrant somatic hypermutation (SHM) in DLBCL and PMBL. The29 
mutations observed in gene were strikingly different of the classical features of SHM. These mutations were mostlySTAT6 30 
transversions, whereas SHM is characterized by transitions occurring twice as frequently as transversions; they mostly targeted A:T base
pairs, whereas SHM affects mostly G:C base pairs; they were located 8,5 Kb from the transcriptional start site whereas SHM mutations are
usually located 2 Kb from the start site. It is interesting to note that hypermutation of BCL6 regulatory region was previously reported to
differ in PMBL and DLBCL. The pattern of somatic mutations reflects both their mechanism of origin and their selection during tumor31 
growth. Since mutations affect the coding sequence, the pattern of mutation may be biased by the selection process. Nevertheless,STAT6 
these results suggest that some atypical SHM or other mutational mechanisms may occur in PMBL.
In the last years, hypomorphic mutations of the gene, most frequently located in the DNA binding domain, have been reportedSTAT3 
to be responsible for autosomic dominant and sporadic hyper-IgE syndrome, a primary immunodeficiency defect and mutations of the32 
STAT1 gene have been associated with type I interferon immunodeficiency. These mutations were shown to be associated with33 
impaired DNA-binding ability. In line with these observations, the analysis of the functional properties of STAT6 mutants identified in
PMBL, also revealed an impaired function in HEK293 cells in EMSA and reporter assays. Three (N417, D419, and N421) of the 4 hotspot
mutations are located in a region which was identified as an important DNA recognition element in the crystal structure of STAT1 and34 
STAT3 dimers bound to DNA, and this may account for their diminished ability to activate STAT6 synthetic reporter constructs. Theβ35 
fourth hot spot (N430), which had a weak effect in these assays and was never observed as sole mutation, corresponds to a residue that is
absolutely conserved in human and mouse STAT proteins.
The arguments for the involvement of mutations in lymphomagenesis are i) their frequency in PMBL, indicating an STAT6 in vivo 
selection during transformation and/or progression; ii) the presence of mutational hotspots; iii) the fact that they target an activated
signaling pathway; iiii) their presence in a Hodgkin cell line with concordant gene amplification. However, the mechanisms through which
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these mutations affect tumor growth remain elusive. Although STAT6 mutants showed an impaired function on short synthetic promoters
in a heterologous cell system, PMBL samples did not show a decreased expression of classical STAT6 targets. This apparent discrepancy
may be due to the fact that the highly complex transcriptional regulation coordinated by STAT6 is not addressed in HEK cellsin vivo 
transfections.
Altogether, our results show that the region encoding the DNA binding domain of is the target of recurrent mutations inSTAT6 
PMBL but not DLBCL. Further investigations are required to identify the mutational mechanisms involved and the oncogenic function
associated with these mutations. This observation opens a wide field of investigation to determine the spectrum and functional
consequences of mutations in tumors, which are critical points in regard to the current development of anti-JAK targeted therapies.STAT 
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Figure 1
Heterozygous mutations in the DNA binding domain of STAT6 in PMBL
Electropherograms showing partial cDNA sequences for the 4 most frequently mutated codons (underligned). Mixed nucleotidesa) STAT6 
are lettered according to IUPAC international code.  This sequence was performed by PCR amplification of genomic DNA (no RNA*
available). Schematic localization of mutations in the region correlating to the nucleotides 1216 to 1581, corresponds to exon 12 (minus 4b) 
bases in the 5  dark gray part), exon 13, and exon 14 (minus 26 bases in the 3  dark gray part) of in the 20 mutated PMBL cases.  This′ ′ STAT6 *
case presents both a missense mutation of codon 419 and a silent mutation of codon 423 (c.A1269G, according to NM_003153.3).
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Figure 2
Functional properties of mutated STAT6 proteins in HEK transfectant cells
Transfected HEK293 cells expressing WT or N417/N430 double mutant (DM) STAT6, selected with G418 (transfection 1: pools, 2: singlea) 
clones), were incubated ( ) or not ( ) with 10 ng/ml interleukin 4 for 24h. Western blots of total protein extracts (7 g) probed with antibodies+ − μ
against P-STAT6 (Tyr-641), total STAT6, and -actin are shown. β Electrophoretic Mobility Shift Assay was prepared using 1 g nuclearb) μ
extracts from mock transfected cells, WT or DM STAT6 HEK293 pools, stimulated with 10 ng/ml interleukin 4 for 6 h, and radiolabeled N3
GAS or N4 GAS probes. Incubation was performed with ( ) or without ( ) an antibody against STAT6 or an excess of cold probe. The+ −
protein/DNA complexes were electrophoresed on the same gel, and are assembled side by side in the figure for better comparison. The
position of the STAT6 containing complexes and of the complexes supershifted (SS) by the antibody are indicated. Phosphorimager
quantification of the radiolabelled complexes is shown in the left plots and Western blot analysis of P-STAT6 and HDAC, used as a loading
control, in nuclear extracts is shown in the right plot. HEK293 cells were co-transfected with expression vectors for WT STAT6, single orc) 
DM STAT6 mutants or a control mock-vector, together with 3 x N3-luc (left plot) or with 3 x N4- luc (right plot) luciferase reporter
constructs. The diagrams show the mean percentage of luciferase activity, after normalization for transfection efficacy, in cells treated (grey
bars) or not (white bars) with 10 ng/ml interleukin 4 for 20 h, compared to WT STAT6 expressing cells (set to 100 ). Error bars shows the%
standard deviation (3 independent experiments). The amount of P-STAT6 in total protein extracts of interleukin 4 treated cells, detected by
immunoblotting, is shown in the lower panel.
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Table 1
Mutation characteristics in exons 12 14.STAT6 –
Number of mutations observed Number of motifs in sequence Number of expected mutation * Ratio observed/expected value P °
Transversions/Transitions 22/6 - 18,7/9,3 1,83 0,2301
A:T base pairs 20 158 12,1 1,65 0,003542
G:C base pairs 8 207 15,9 0,5
Dinucleotides Number of mutations observed Number of dinucleotide in sequence Number of expected mutation Ratio observed/expected valueP 
AA 13 20 3,077 4,225 0,0000007
AC 4 19 2,923 1,368 0,5198589
AG 7 20 3,077 2,275 0,0249483
AT 7 13 2,000 3,500 0,0014790
CA 8 27 4,154 1,926 0,0563318
CC 0 34 5,231 0,000 0,0068772
CG 0 9 1,385 0,000 0,3715297
CT 1 32 4,923 0,203 0,0509948
GA 10 23 3,538 2,826 0,0012213
GC 1 24 3,692 0,271 0,1614790
GG 0 33 5,077 0,000 0,0066356
GT 0 24 3,692 0,000 0,0410432
TA 0 2 0,308 0,000 1,0000000
TC 0 26 4,000 0,000 0,0254541
TG 5 42 6,462 0,774 0,6709954
TT 0 16 2,462 0,000 0,1554094
 * Expected mutation frequencies were calculated according to the sequence composition, assuming random targeting of the mutations at a 28/365 rate for single nucleotide changes and 56/364 rate for
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 * Expected mutation frequencies were calculated according to the sequence composition, assuming random targeting of the mutations at a 28/365 rate for single nucleotide changes and 56/364 rate for
dinucleotide mutations.
 ° Statistical comparisons were done with the exact binomial test, which compares the observed frequency to the expected one under null hypothesis. The dinucleotides which were significantly targeted
by mutations are highlighted in bold.
Table 2
Characteristics of the cases according to the presence or absence of a mutation detected in exons 12 14.STAT6 –
Mutation (n 20)STAT6 = no mutation (n 35)STAT6 = valuep *
median age at diagnosis (min-max) 37.5 (22 59)– 32 (17 73)– 0,43
females/males ratio 13/7 15/20 0,16















not determined 3 5
 * Age at diagnosis was compared with Wilcoxon rank test and the other characteristics were compared with Fisher s exact test (using only informative cases).’
STAT6 mutations in mediastinal B-cell lymphoma
Blood . Author manuscript
Page /10 10
Table 3
Expression of loci containing one or more confirmed STAT6 binding motifs in PMBL cases.
GENE microarray ID No mutation (n 5)STAT6 = ° Mutation (n 7)STAT6 = ° Fold Change # Student t test valuep *
FCER2 35220 −1,26 −0,24 2,02 0,26
17521 −1,37 −0,36 2,01 0,37
IL4 25233 −0,37 0,03 1,32 0,32
34968 −0,46 −0,08 1,30 0,40
IL4R 28597 1,05 1,41 1,28 0,15
19256 1,69 2,09 1,32 0,25
CCL17 29233 −1,26 −0,82 1,36 0,60
CD40 27399 0,11 0,53 1,34 0,07
16913 0,10 0,45 1,28 0,12
BCL2L1 16454 0,02 −0,15 0,89 0,30
24267 0,10 −0,03 0,92 0,53
IL4I1 149016 2,25 2,40 1,11 0,75
149017 1,57 1,94 1,29 0,23
 ° Mean expression levels (log2) in cases with (n 7) or without (n 5) STAT6 mutation (from Rosenwald, 2003).= = 19
 # Fold change: ratio of mean expression in mutated cases relative to WT cases.
 * p values were not corrected for multiple comparisons.
